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Abstract 
Oral extended release products offer potential advantages in patient 
compliance and therapeutic outcomes like sustained blood levels with 
attenuation of adverse effects. In neuropsychiatric disorders like depression, 
most of the formulations serve a marketing objective rather than a clinical 
objective. The present investigation was aimed to develop a once daily 
sustained release formulation for delivery of an acid-labile, water soluble 
antidepressant, duloxetine HCl. The formulation was pragmatically designed 
using blend of natural and synthetic polymeric biomaterials that it releases 
the drug at alkaline pH in a sustained manner. The basic intention was to 
develop a tablet formulation with hydrophilic matrix core, using blend of 
release retarding natural biodegradable polymers such as guar gum, carbopol 
71G-NF (a synthetic carbomer) and C-Pharm® gel. Barrier coating using 
HPMC-E5 was given to retard the initial release followed by enteric coating 
with HPMC-AS to prevent exposure of drug in acidic mileau of the stomach. 
The formulation exhibited desired release pattern and was described best-fit 
by Hixon-Crowell model. Stability analysis under stress conditions up to one 
month displayed good reproducibility. The matrix tablets successfully 
decreased the symptoms of depression (significant decrease in immobility 
time) in a rat forced swimming model. Pharmacokinetic data of the 
formulation revealed (tmax ~ 6 h, Cmax ~ 1157.58 ng/ml, mean AUCt~11145.04 
ng*h/ml, and Ka~1.07h-1) good correlation in all animals. 
  
Keywords: Matrix tablets; Duloxetine HCl; Sustained release; Enteric 
coating; Hixon-crowell model 
 
Introduction  
Depression is the 4th leading cause of disability 
worldwide and it will be the second leading cause of 
disability by 2020 second only to ischemic heart 
disease as reported by the WHO. A sharp increase in 
psychiatric disorders have been observed since the late 
1950s, which is clear from the fact that 10% to 15% of 
prescriptions written in the U.S. are for medications 
intended to depression as a predominant disorder [1]. 
Depression is not a homogenous disorder, but a 
complex  phenomenon  which  has  many  subtypes and  
 
probably more than one etiology [2]. In one report by 
London school of Economics in 2006, “one in six of us 
would be diagnosed as having depression or chronic 
anxiety disorder” [3]. Depression is a kind of 
manifestation that can affect any age group. 3-6% 
children of age 4-16 years, who attended the child 
psychiatry out-patient clinics in Delhi, were found to 
be attacked by depression [4]. 
Most antidepressant drugs exert their actions on the 
metabolism of monoamine neurotransmitters and their 
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receptors, particularly norepinephrine and serotonin 
[5]. The major classes of drugs used to treat depression 
are the tricyclic antidepressants (TCAs), selective 
serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine 
and sertraline), heterocyclics (e.g., bupropion), 
monoamine oxidase (MAO) inhibitors and a few other 
compounds such as venlafaxine and duloxetine, which 
inhibits specifically the reuptake of both serotonin and 
norepinephrine [6]. As on date, more than 80% of the 
therapeutic drugs are administered by the oral route and 
rated among high patient compliant dosage forms.  
Amongst these the immediate release tablets give the 
saw tooth pattern of plasma drug concentrations, which 
are further associated with adverse events at maximum 
concentration and loss of therapeutic effect at 
minimum concentration. This leads to intolerability or 
frequent dosing of many major categories of drugs 
including antidepressants. As incapability of the 
medication to deliver the drug at a proper time in a 
proper concentration to the required site is a major 
determinant of the therapeutic response achieved. 
Therefore these days drug reformulations are designed 
with the aim of reducing the pharmacokinetic 
inadequacies associated with the orally administered 
immediate release preparations. Modified dosage forms 
for oral drug-delivery systems often contain higher 
doses of a beneficial substance than do immediate-
release preparations[7], and are typically designed to 
produce more uniform absorption of the beneficial 
substances delivered there from. Modified release 
formulations of antidepressant agents have the potential 
to improve tolerability by reducing adverse effects 
early in the course of therapy - a critical period of 
dramatic failure. [8] Duloxetine HCl is as a serotonin 
and norepinephrine reuptake inhibitor (SNRI) which 
inhibits dopamine reuptake and has no significant 
affinity for histaminergic, dopaminergic, cholinergic or 
adrenergic receptors. [9] Duloxetine HCl is an acid 
labile drug moiety. The development of a modified 
release formulation was preferred due to the various 
advantages offered which include the prevention of 
adverse events associated with the fluctuating plasma 
profile obtained with the immediate release 
formulations [7]. Hence, the aim of the study was to 
design i) a suitable delivery system which protects the 
drug from the acidic environment and allow the release 
of the drug for a prolonged period using various release 
retarding, film coating and enteric coating polymers. 
The formulations were so designed that they do not 
release the drug in the acidic pH (stomach) 
consequently resulting in drug absorption after about 
two hours of the drug administration in sustained 
manner. ii) Characterization and evaluation for in vitro 
release, stability studies, pharmacodynamic and in vivo 
pharmacokinetic studies of the delivery system.  
 
Materials and methods 
Duloxetine Hydrochloride was a generous gift from 
Ranbaxy Laboratories Ltd. (Gurgaon, India). HPMC-
E5, HPMC-AS and Guar gum were obtained as gift 
samples from Colorcon Asia Pvt. Ltd. (Mumbai, India) 
and Dabur Pvt. Ltd. (Ghaziabad, India), respectively. 
All the excipients and solvents used were of analytical 
grade. 
 
Formulation of a matrix tablets 
Matrix tablets of duloxetine HCl containing different 
amounts of polymer blend were prepared by direct 
compression along with magnesium stearate (lubricant) 
and talc (glidant). Tablets were made by first mixing all 
the excipients along with the drug thoroughly followed 
by sieving to obtain a uniform blend. The dry mix was 
blended uniformly with lubricant and glidant and then 
compressed into tablets on single punch machine 
(Modern Engg., New Delhi) using 8 mm. The core 
composition of matrix tablets containing different 
polymers in varying ratios has been shown in Table 1. 
 
Coating of duloxetine HCl matrix tablets 
Barrier coating of core tablets 
The tablets were barrier coated at 2.5% w/w of coat 
weight using Gans-coater® (Gansons Limited, Thane, 
India) with an inlet air temperature of 35º C. The 
coating solution (3.0% w/v) containing HPMC E5 was 
prepared in mixture of ethanol and water (8:2) 
respectively.  Di-butyl phthalate (15% w/w) was used 
as the plasticizer. A clear solution was obtained by 
continuous stirring on magnetic stirrer for sufficient 
period of time. The coating process was continued in 
order to obtain a required level of coat weight.  
 
Enteric coating of core tablets 
Batches obtained after 2.5% level barrier coating were 
further coated with enteric coating solution at different 
levels (3-13%), which were further used for release 
study. The enteric coating solution (3.0% w/v) 
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containing HPMC AS was prepared in mixture of 
ethanol and water (8:2). Di-butyl phthalate (15% w/w) 
was used as the plasticizer. The solution was stirred on 
magnetic stirrer for sufficient period of time. 
 
 
Table 1. Formulations containing various polymers ratios in the matrix core tablet 
 
 
Evaluation of matrix tablets 
Diameter and thickness measurement 
All the batches were evaluated for diameter and 
thickness with the aid of a Vernier Caliper, in order to 
determine the uniformity in the size of batches.  
 
Table 2. Comparative study of different drug 
release kinetic models [* Regression coefficient (R2)] 
Hardness and friability 
Hardness and friability of the tablets was determined 
using Monsanto hardness tester and Roche friability 
tester for all the batches respectively.  
 
Table 3. Time of immobility of animals during FST 
in both the test sessions (n=6)  
 
Mean time  
(in sec) 
Standard Error 
Mean 
Tukey’s test Group 
name 
Control Test Control Test Control test 
Group A 
(2 h) 
72 71.5 17.90 19.15 0.028 0.026 
Group B 
(4 h) 
60.83 41.33 11.21 6.05 1.74 3.22 
Group C 
(6 h) 
57.33 40.83 14.10 5.45 1.17 3.02 
Group D 
(8 h) 
61.33 44.66 10.19 11.43 1.64 3.39 
Group E 
(12 h) 
84.16 66.33 14.36 6.04 1.24 2.95 
Group F 
(24 h) 
82.50 62.00 14.94 8.13 1.37 2.52 
Formulation 
Code 
Drug 
(mg/tablet) 
Carbopol  
71G NF  
(mg/tablet) 
Guar gum  
(mg/tablet) 
C-Pharm® gel 
(mg/tablet) 
Magnesium 
stearate 
(mg/tablet) 
Talc 
(mg/tablet) 
MCC 
(mg/tablet) 
Total 
weight 
APL1 40 90 -- -- 4.5 4.5 81.0 220 
APL2 40 112.5 -- -- 4.5 4.5 58.5 220 
APL3 40 135 -- -- 4.5 4.5 36.0 220 
CPG1 40 90 -- 83.25 2.25 4.5 -- 220 
GG1 40 90 2.25 81.0 2.25 4.5 -- 220 
GG2 40 90 4.5 78.75 2.25 4.5 -- 220 
GG3 40 90 9.0 74.25 2.25 4.5 -- 220 
C3G2 40 67.5 4.5 101.25 2.25 4.5 -- 220 
Different Release Mechanisms for the Batch C3G2L1 
 Equation Slope (n) R
2 
Best Fit 
Model 
Zero 
Order 
Release 
F = k0. T - 0.905 - 
First 
Order 
Release 
F = 100 (1- e -k1t ) - 0.938 - 
Higuchi’s 
Release F = kH√t - 0.925 - 
Hixson-
Crowell 
Release 
F = 100 [1-(1-KHCt)3] - 0.970 
Hixon- 
Crowell 
Korsmeye
r-Peppas 
Release 
F = kptn 1.540 0.963 - 
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Drug content 
Ten tablets from each batch were weighed and 
powdered in a mortar and pestle. Powder equivalent to 
the drug in each tablet was weighed and dissolved in 
water to obtain a solution of 1 mg/ml. The solution was 
sonicated for 5 min then subsequently centrifuged for 
10 min at 4000 rpm. After centrifugation, the 
supernatant was taken and then diluted with water. The 
drug content was then calculated by analyzing the 
sample using a UV-Visible spectrophotometer 
(Shimadzu -1601, USA) at λmax of 291nm. 
 
In-vitro release studies 
The in vitro release profile of the drug in coated tablets 
was carried out according to USP- XXIII method for 
delayed release tablets (Method A). Dissolution studies 
were carried out using USP apparatus type-II i.e. 
paddle type at 50 rpm and at a temperature of 37±0.5 
ºC. Initial studies were performed in 0.1N HCl (pH 1.2) 
for 2 hours followed by phosphate buffer (pH 6.8) up 
to 24 h. The pH was adjusted with the aid of 2N HCl or 
2N NaOH. Samples were withdrawn at predetermined 
time intervals and replaced with fresh media. They 
were then analyzed using UV-spectrophotometer 
(Shimadzu-1601, USA) at λmax of 291 nm. 
 
HPLC analysis 
The method for the drug estimation in plasma was 
validated by RP-HPLC system at λmax - 232 nm 
(consisted of a LC-10 AT VP Shimadzu pump 
equipped with a SPD-10 AV P Shimadzu UV- visible 
detector) using BDS Hypersil C-8 reverse phase 
column (150 × 4.6 mm, S-5 µ) in a mobile phase 
Phosphate buffer (pH 2.5) and organic phase (methanol 
: tetrahydrofuran, 80:20 ) in the ratio of 55: 45 with 
flow rate of 1.0 ml/min at  40°C. The volume of 
injection used was 20 μl. 
 
Physiochemical compatibility studies 
The physicochemical compatibility between drug and 
various excipients (Carbopol, C-Pharm Gel and guar 
gum) was investigated in order to avoid costly material 
wastage and time delays. The 1:1 physical mixtures of 
these excipients with the drug were subjected to DSC 
analysis. Because the gathering of real-time stability 
and compatibility data is incomplete in the early stages 
of development, stress testing and accelerated stability 
methods were also used for predicting ambient 
condition interactions and rates of degradation for the 
drug candidate. Tablets were exposed to accelerated 
conditions (40ºC ± 2°C/75% RH ± 5% RH) for 
different time periods (0, 15, 30, 45 days), and 
evaluated for the different physicochemical parameters 
viz. appearance, thickness, hardness, diameter, drug 
content, in vitro release studies and chemical drug 
degradation (using validated HPLC method). The 
results of DSC and HPLC were combined in order to 
assess the incompatibility and stability.  
 
In–vivo pharmacodynamic studies  
Animals were housed in accordance with the guidelines 
of Institutional Animal Care and Use Committee 
(IACUC) and were fed on standard normal pellet diet 
(Aashirwad Industries, Chandigarh) along with water 
ad libitum. 
 
Rat forced swimming test (FST) 
FST a behavioral phenomena, was performed using 
Spargue-Dawley rats weighing 190-225 g. Thirty six 
animals were selected (divided into six groups of six 
animals each) for the study. Swimming sessions were 
conducted by placing the rats in glass beaker (46 cm × 
20 cm × 22 cm) containing water maintained at the 
height of 30 cm, so that rats could not support 
themselves by touching the bottom with their feet, at 
the temperature of 23-25°C. Three swimming sessions 
were conducted: an initial 15-min pretest followed 24 h 
later by a 5-min test; observations of this session were 
kept as control and then again followed 24 h later by a 
5-min test [8]. Tablets were given orally to rats in a 
dose equivalent to 40 mg/kg of drug. Following the 
swimming sessions, the rats were removed from water, 
dried and then returned to their home cages [9]. The 
water in the beaker was changed after every trial. A 
time-sampling technique was employed to score the 
behavior during the test period and statistical analysis 
was applied on the data using Tukey’s test to compare 
the values of the control group from experimental 
groups [10]. 
 
In- vivo pharmacokinetic studies 
In order to determine the plasma level profiles of 
duloxetine HCl, tablets (in a dose equivalent to 40 
mg/kg of drug) were administered orally in rats (n=5, 
180-250 g) [11]. After oral dose, blood samples were 
withdrawn at intervals of 0, 2, 4, 6, 8, 12 and 24 h. 
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Blood samples were collected in micro-centrifuge tubes 
containing heparin and were centrifuged (5000 rpm for 
5 min). The separated plasma was kept at –20°C if not 
analyzed immediately. The drug extracted from the 
plasma using acetonitrile (1 ml in 500 μl of plasma) 
was subjected to HPLC analysis. All the 
pharmacokinetic parameters were calculated for 
individual animals using Jandel software (Sigma stat® 
2.0). Then plasma profile of all the animals were 
plotted as mean±SD. Moreover, SPSS®(version 16.0) 
curve-fitting program using least square technique was 
used to evaluate the correlation between the mean 
plasma concentration(AUC0-24h) against different time 
intervals and compare their relative goodness of fit for 
models where a single dependent variable is predicted 
by a single independent variable or by a time variable 
as shown in Fig. 8.  
 
Results and discussion  
Tablets batches were tested for uniformity of weight as 
per I.P. and were found to be within specified limits. 
Other parameters hardness, diameter, thickness, 
friability and drug content of various formulations were 
found to be in range of 12.0 - 16.5 kg/cm2, 8.02 ± 0.02 
- 8.46 ± 0.02(mm ± S.D), 4.28 ± 0.03 - 5.0 ± 0.02 (mm 
± S.D), 0.02% - 0.14% and 97.98% – 100.72% 
respectively. 
Preliminary studies were carried out using various core 
tablet matrix systems for modified delivery of 
duloxetine HCl. The effect of fillers like MCC and C-
Pharm® gel was evaluated for the release 
characteristics of the drug. Three batches containing 
duloxetine HCl and Carbopol 71G NF (40%-APL1, 
50%-APL2, and 60%-APL3) were prepared by direct 
compression using microcrystalline cellulose (MCC) as 
the filler (Table 1). In vitro release profile showed burst 
release after 8 h for Batch APL1 (Figure 1) which 
might be due to low concentration of polymer and 
decrease in interactions between the carbopol polymer 
linkages by MCC [12-13]. However, in case of batches 
APL2 and APL3, the complete drug could not be 
released after 24 h may be due to higher content of 
carbopol thus overcoming the disintegrating power of 
MCC [14]. 
Further studies were performed by replacing MCC with 
C-Pharm® gel to provide complete release 
accompanied with the desired initial release 
retardation. Batch containing duloxetine HCl and 
Carbopol (90 mg) with 37.08% of C-Pharm® gel 
(CPG1) was prepared and exhibited initial drug release 
of 8.88% in 2 h and 100.81% in 24 h.  
 
 
 
Figure 1. Plot of cumulative percent release of 
duloxetine HCl from matrices containing Carbopol 
71G NF and MCC (APL1, APl2 and APL3) mean ± 
SD; n=3. 
 
Matrix tablets containing carbopol and guargum 
using C-Pharm® gel as filler 
Further, investigation was designed with guar gum as a 
dry binder at low concentration and C-Pharm® gel as 
filler which offered additional benefits such as ease of 
formulation, complete release accompanied with the 
desired initial release retardation. 
Three batches (GG-1, GG-2, and GG-3) containing 
duloxetine HCl , Carbopol 71G-NF (90 mg) with 
different amounts of guar gum 1%, 2% and 4% 
respectively and one batch with 67.5 mg carbopol 71G 
NF and 2% guar gum (C3G2) were prepared by direct 
compression using C-Pharm® gel as the filler. In-vitro 
dissolution profile of Batch GG1 showed a cumulative 
percent release of 7.13% in first 2 h; 19.70% in 6 h and 
99.77% in 24 h. Tablets of batch GG2 showed a 
cumulative percent release of 4.55% in first 2 h; 
11.92% in 6 h and 77.43% in 24 h (Figure 2). In case of 
batch GG3, 5.50% drug release in first 2h; 10.94% in 6 
h and 41.16% in 24 h. Tablets of C3G2 exhibited 
cumulative percent release of 8.11% in 2h; 40.85% 
release in 6 h and 96.29% release in 24 h. The 
concentration of Carbopol remained same in all three 
batches, however with increasing the amount of guar 
gum (GG-1, GG-2, and GG-3); there was decrease in 
the drug release from the respective formulations.  
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Figure 2. Plot of cumulative percent release of 
duloxetine HCl from matrices containing Carbopol, 
Guar gum and C-Pharm® gel (GG-1, GG-2, GG-3 
and C3G2) mean ± SD; n=3. 
 
High initial retardation was achieved in all batches 
GG1, GG2 and GG3 but no complete release of drug 
was found to occur at 24 h except batch GG1(Figure 
2). However, in case of batch C3G2 the complete drug 
was released in sustained manner. This formulation 
was enteric coated in order to prevent drug degradation 
in acidic environment of the stomach. Initially, a 
barrier coat of HPMC-E5 which would act as a seal 
coat was given then eventually a second coating with 
enteric coated polymer was provided as the enteric 
coating material on dissolution creates an acidic 
environment which may lead to degradation of the drug 
that can be prevented by the barrier layer. 
The drug release profile of the seal coated tablets 
(coated with HPMC-E5, 2.5% coat weight) of final 
batch (C3G2FC) revealed that seal coating itself was 
not retarding the drug release to a great extent (Figure 
3). This is done just to prevent interaction between 
enteric coated polymer and drug in the matrix.  
 
Enteric coating of batches GG1 and C3G2 
In the subsequent study, the purpose of the enteric coat 
was to delay the release of duloxetine HCl until it 
reached small intestine because drug is degradable in 
acidic stomach. HPMCAS (Hydroxy 
propylmethylcellulose acetate succinate) was used for 
enteric coating. Tablets were coated with enteric 
polymer to different level to tailor the drug release. 
Cumulative percent release of drug after 24 h from 
both the uncoated (GG1) and coated batches (GG1L1, 
GG1L2 and GG1L3), are shown in Figure 4. 
 
Figure 3. Plot of cumulative percent release of 
duloxetine HCl from Barrier Coated Tablets. 
 
The tablets of batch GG1 containing 40% carbopol 
71G NF and 1% guar gum, showed a cumulative 
percent release of 7.13% in first 2 h and was 99.77% in 
24 h as depicted in Figure 2. In order to prevent initial 
drug release the tablets were enteric coated with 
HPMCAS at three different levels of 3%, 8% and 13% 
for batches GG1L1, GG1L2 and GG1L3 respectively. 
Batch GG1L1 showed a release of 1.22% after 2 h and 
97.33% at the completion of 24 h was observed (Figure 
4).  
A negligible amount of the drug was released till 2 h 
and also drug was released in a sustained manner with 
complete release of the drug at 24 h. As coat weight of 
8% (GG1L2) drug release was negligible at 2 h but 
release of the drug was much sustained although 
complete drug was released at final hours. In case of 
batch GG1L3 with highest coat weight of 13% the drug 
release was highly retarded and the same time tablet 
failed to release the complete drug. Hence, these two 
batches were not suitable as sustained release tablet. 
Batch (C3G2) was also enteric coated to develop 
sustained release of duloxetine HCl using HPMCAS. 
The batch C3G2 (uncoated) showed a cumulative 
percent release of 8.11% in first 2 h and was 96.29% in 
24 h (Figure 2). In order to prevent drug release in 
stomach, the batch was enteric coated with HPMCAS 
at four different levels 2%, 3%, 4.4% and 6.8% for 
batches C3G2L1, C3G2L2, C3G2L3 and C3G2L4. 
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Figure 4. Plot of cumulative percent release of 
duloxetine HCl from matrices containing carbopol, 
Guar gum and C-Pharm® gel coated at various 
levels with HPMCAS (3% w/w) mean ± SD; n=3. 
 
Batch C3G2L1 showed a release of 2.24% after 2 h and 
98.53% at the completion of 24 h. A negligible amount 
of the drug was released till 2 h and also drug was 
released in a sustained manner with complete release of 
the drug at 24 h (Figure 5). At coat weight of 3% drug 
release was negligible at 2 h but release of the drug was 
more sustained although complete drug was released at 
final hours. In case of batch C3G2L3 with coat weight 
4.4%, the drug release was much more sustained which 
was not desirable. On further increase the coat weight 
to 6.8% for batch C3G2L4, the release was highly 
sustained. Hence these three batches C3G2L2, C3G2L3 
and C3G2L4 were not found to be suitable as sustained 
release formulation as none of these were able to 
provide a sustained release of the chosen candidate in 
the later hours. Batch C3G2L1 was observed to be the 
most suitable because it prevented drug release in the 
stomach and further provided sustained release to a 
sufficient extent i.e. it provided a uniform rate of drug 
release in the lower segment of the GIT. Hence, the 
batch C3G2L1 was further subjected to animal studies. 
The compatibility between duloxetine HCl and the 
various excipients (Carbopol 71G NF, C-Pharm® gel 
and guar gum) used in preparation of the tablets (Batch 
C3G2L1) was tested using thermal (DSC) and well 
developed analytical RP-HPLC method. The DSC 
curve of the pure drug exhibited a sharp peak at 
164.55°C, corresponding to its melting point (Figure 
6a). The DSC curve of the 1:1 mixtures of the 
excipients and the drug showed sharp drug peak 
indicative of its melting point (Figure 6b). This 
indicates the absence of physicochemical interaction of 
duloxetine HCl with different excipients used in the 
study. 
Further, HPLC-based accelerated stability studies were 
conducted on the tablets by kept in high-density 
polyethylene bottles sealed with parafilm, at 40ºC/75% 
relative humidity (Table 5). The studies indicated the 
complete stability of the formulation even after 
exposure to accelerated stability conditions.  
Also, the kinetics of the release behavior was assessed 
for batch C3G2L1 (Carbopol-Guar gum-HPMCAS 
coated) by mathematical modeling. The formulation 
complied with higher correlation with Hixson-
Crowell’s cube root of time equation release 
mechanism as depicted in Table 2.  
 
 
 
Figure 5. Plot of cumulative percent release of 
duloxetine HCl from matrices containing Carbopol 
(30%), Guar gum (2%) and C-Pharm® gel coated 
at various levels with HPMCAS (3% w/w) mean ± 
SD; n=3. 
 
Pharmacodynamic studies using rat forced 
swimming test 
The data obtained from the six groups (Table 3) 
showed that there was no statistical significant 
difference (P<0.05) in the behavior of the animals of 
Group A (dose was given 2 h before the test session) 
whereas statistical difference (P<0.05) in the 
immobility behavior was observed in case of Group B, 
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Group C, Group D, Group E and Group F animals 
(dosing was done 4 h, 6 h, 8 h, 12 h and 24 h 
respectively before the test session) (Figure 7). From 
the results it was concluded that the release of the drug 
from the formulation was after 2 h and was released up 
to 24 h after the administration. Thus, the investigation 
suggested the effectiveness of duloxetine (40 mg/kg in 
the form of matrix system) in reducing FST-induced 
depressive behavior. 
 
 
 
(a) 
 
 
(b) 
 
Figure 6. DSC Thermograms of the physical mixture of the drug with the tablet excipients (1:1) (a) 
Duloxetine HCl: Carbopol 71 G NF (b) Duloxetine HCl: guar gum. 
 
 
 
 
 
 
In- vivo pharmacokinetic study 
The sustained release performance of the developed 
dosage form was evaluated by in-vivo pharmacokinetic 
studies in the rats. Various pharmacokinetic parameters 
such as Cmax, Tmax, AUCt, and Ka were obtained after 
drug plasma level studies. After administration of 
duloxetine (40 mg/kg), the drug plasma concentrations 
were monitored for 24 h and summarized in Table 4. 
The mean pharmacokinetic parameters (n=5) for batch 
C3G2L1 (Table 4) inferred that maximum therapeutic 
effect of the drug was observed within 6 h of 
administration and no drug release occurred in the 
initial 2 h which indicate the effectiveness of the 
enteric coat applied on the formulation. All the 
pharmacokinetic parameters obtained i.e. Cmax, Tmax, 
AUC, and Ka indicated good correlation in all the 
animals. The mean plasma concentration (AUC0-24h) 
time profile was subjected to curve fitting models using 
least square method. The data for mean plasma 
concentration vs time showed best fit in cubic model 
with correlation (r2 = 0.556, (p<0.05))  for batch 
C3G2L1  at different time intervals.  
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Figure 7. Comparison of the time of immobility in 
different groups during the two test sessions of FST 
(1-Control, 2-Test). 
 
Stability analysis  
Stability studies were performed at 40ºC/75 % RH for 
one month to assess the stability of the Batch C3G2L1. 
After storage the tablets were subjected to assay of 
drug content and dissolution by a validated RP-HPLC 
method at specified time intervals of 0, 15 and 30 days 
respectively. No changes in the physical appearance 
and drug content were noted (Table 5). The statistical 
comparison (ANOVA followed by Tukey’s test) using  
 
 
 
Jandel software (Sigma stat® 2.0) showed that there 
was no significant difference in the amount of 
duloxetine HCl released at the end of 24 h dissolution 
study in all the stability samples. 
 
Table 4. In-vivo pharmacokinetic parameters of 
tablet formulation in rats 
 
Subject 
Rats 
(n=5) 
Tmax 
(h) 
Cmax 
(ng/ml) 
AUC0-∞   
(ng*h/ml) 
AUCt 
(ng*h/ml) Ka 
1 6 870.42 15543.21 8628.92 0.92 
2 6 1157.58 61026.81 11184.81 1.18 
3 6 1603.58 33048.27 13269.27 1.00 
4 6 1137.79 41241.07 11651.57 1.17 
5 6 1021.37 18777.36 10990.61 1.07 
Mean 6 1158.15 33927.34 11145.04 1.07 
SD 0.98 274.01 18412.92 1667.72 0.11 
 
Selection of a proper release retardant matrix 
composition for duloxetine HCl  
The criteria for the selection of the polymer matrix 
formers was based on the fact of polymeric hydration 
to protect the tablet from rapid disintegration and 
dissolution and to extend the drug release rate. Various 
types of polymers and fillers were employed to form 
the matrix systems, e.g. Carbopol 71G-NF 
(carboxypolymethylene), a synthetic HMW acrylic acid 
polymer, pregelatinised starch (C-Pharm gel), guar 
gum, etc.  
Studies were carried out using combination of 
Carbopol 71G-NF (granular grade of Carbomer) as the 
release retarding polymer in the matrix system along 
with Guar gum (GG1, GG2, GG4 and C3G2) were 
prepared. From the in-vitro study results it was inferred 
that the combination of Carbopol 71G-NF (30%) with 
guar gum (2%) (C3G2) is the most appropriate choice 
for the development of the desired matrix system but 
enteric coating is required to prevent initial drug 
release which is well known for their property to 
dissolve and release the contents of the dosage form on 
reaching the region where the pH is optimal for 
dissolution of the coat [15]. To retard the premature 
release of the drug in the upper segment of the GIT, 
HPMC-AS (3.0% w/v) was used at different coating 
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levels. Thus, Batch C3G2L1 was concluded to be the 
best formulation in the present study, because it 
prevented   drug  release  in  the  stomach   and   further 
 provided sustained release to a sufficient extent i.e. it 
provided a uniform rate of drug release in the lower 
segment of the GIT.  
 
 
 
 
 
 
Figure 8. Curve fitting using least square method for determination correlation between mean plasma 
concentration (AUC0-24h) against time at different intervals a) data fitting in different models b) confidence 
interval (at 95%) for fitting levels. 
 
 
Rat forced swimming test (FST) 
The pharmacodynamic performance of enteric coated 
sustained release tablets of duloxetine HCl of batch 
C3G2L1 was assessed with the help of well established 
rat forced swimming test (FST). The immobility period 
was recorded for each group at each time point. This 
immobilization represents a state of desperation in the 
rodents, which is a symptom seen in depression. 
Duloxetine HCl reduced the immobility time and thus 
resulted into increased activity, which is reflective of 
the efficacy of the drug in the present formulation. The 
data obtained was subjected to statistical analysis using 
Tukey’s Test to compare the values of the control 
group to the other experimental groups.  
Various mathematical models have been suggested for 
the depiction of drug release mechanism to check the 
goodness of fit, like zero order release kinetics, first 
order release kinetic, Higuchi’s square root of time 
equation [16], Hixson-Crowell’s cube root of time 
equation [17] and Korsmeyer-Peppas power law 
equation [18-19]. The goodness of fit was evaluated by 
correlation coefficient values (R2).  
 
Table 5. Drug content of the Batch C3G2L1 after 
accelerated stability studies for 30 days (*Data 
represents mean±S.D) 
 
Time 
points 
Drug content (%)* 
0 day 100.01±0.02 
15 day 99.86±0.03 
30 day 99.91±0.02 
 
Thus, the mathematical model indicated that the drug 
release is mainly because of the change in surface area 
and diameter of the particles or tablets with time and 
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mainly applies in the case of systems that dissolve or 
erode over time. 
From the pharmacokinetic data obtained, it was 
inferred that maximum therapeutic effect of the drug 
was observed within 6 h of administration and no drug 
release occurred in the initial 2 h which indicate the 
effectiveness of the enteric coat applied on the 
formulation.  
 
Conclusions 
Batch C3G2L1 was observed to be the most suitable 
for delaying the drug release for 2 h. It showed drug 
release of 2.24% at 2 h and 98.53% after 24 h. Stability 
studies were performed at 40C/75% RH for 30 days 
indicating the batch C3G2L1 to be a stable 
formulation. In the pharmacodynamic model of 
depression (rat forced swimming test), the tablets were 
successful in decreasing the symptoms of depression. 
Further, pharmacokinetic data of batch C3G2L1 
revealed that formulation gives tmax of 6 h and drug was 
found released even at the end of 24 h. Hence, the 
enteric-coated (HPMCAS) matrix composition 
consisting of Carbopol 71G NF as a ‘release retarding 
agent’ in combination guar gum, can be successfully 
used to protect the premature release of the hydrophilic 
drug moiety in the acidic environment of the GIT. The 
enteric coated tablets protected the drug degradation in 
the acidic environment. 
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